Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles

Abstract Radiolabeled magnetic nanoparticles are promising candidates as dual-modality-contrast-agents (DMCA) for diagnostic applications. The immunocompatibility of a new DMCA is a prerequisite for subsequent in vivo applications. Here, a new DMCA, namely Fe3O4 nanoparticles radiolabeled with 68Ga,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria-Argyro Karageorgou, Dimosthenis Stamopoulos
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f9189ee69ced4cb9ba8b1377a0369d06
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f9189ee69ced4cb9ba8b1377a0369d06
record_format	dspace
spelling	oai:doaj.org-article:f9189ee69ced4cb9ba8b1377a0369d062021-12-02T15:38:11ZImmunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles10.1038/s41598-021-89117-32045-2322https://doaj.org/article/f9189ee69ced4cb9ba8b1377a0369d062021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89117-3https://doaj.org/toc/2045-2322Abstract Radiolabeled magnetic nanoparticles are promising candidates as dual-modality-contrast-agents (DMCA) for diagnostic applications. The immunocompatibility of a new DMCA is a prerequisite for subsequent in vivo applications. Here, a new DMCA, namely Fe3O4 nanoparticles radiolabeled with 68Ga, is subjected to immunocompatibility tests both in vitro and in vivo. The in vitro immunocompatibility of the DMCA relied on incubation with donated human WBCs and PLTs (five healthy individuals). Optical microscopy (OM) and atomic force microscopy (AFM) were employed for the investigation of the morphological characteristics of WBCs and PLTs. A standard hematology analyzer (HA) provided information on complete blood count. The in vivo immunocompatibility of the DMCA was assessed through its biodistribution among the basic organs of the mononuclear phagocyte system in normal and immunodeficient mice (nine in each group). In addition, Magnetic Resonance Imaging (MRI) data were acquired in normal mice (three). The combined OM, AFM and HA in vitro data showed that although the DMCA promoted noticeable activation of WBCs and PLTs, neither degradation nor clustering were observed. The in vivo data showed no difference of the DMCA biodistribution between the normal and immunodeficient mice, while the MRI data prove the efficacy of the particular DMCA when compared to the non-radiolabeled, parent CA. The combined in vitro and in vivo data prove that the particular DMCA is a promising candidate for future in vivo applications.Maria-Argyro KarageorgouDimosthenis StamopoulosNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Maria-Argyro Karageorgou Dimosthenis Stamopoulos Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles
description	Abstract Radiolabeled magnetic nanoparticles are promising candidates as dual-modality-contrast-agents (DMCA) for diagnostic applications. The immunocompatibility of a new DMCA is a prerequisite for subsequent in vivo applications. Here, a new DMCA, namely Fe3O4 nanoparticles radiolabeled with 68Ga, is subjected to immunocompatibility tests both in vitro and in vivo. The in vitro immunocompatibility of the DMCA relied on incubation with donated human WBCs and PLTs (five healthy individuals). Optical microscopy (OM) and atomic force microscopy (AFM) were employed for the investigation of the morphological characteristics of WBCs and PLTs. A standard hematology analyzer (HA) provided information on complete blood count. The in vivo immunocompatibility of the DMCA was assessed through its biodistribution among the basic organs of the mononuclear phagocyte system in normal and immunodeficient mice (nine in each group). In addition, Magnetic Resonance Imaging (MRI) data were acquired in normal mice (three). The combined OM, AFM and HA in vitro data showed that although the DMCA promoted noticeable activation of WBCs and PLTs, neither degradation nor clustering were observed. The in vivo data showed no difference of the DMCA biodistribution between the normal and immunodeficient mice, while the MRI data prove the efficacy of the particular DMCA when compared to the non-radiolabeled, parent CA. The combined in vitro and in vivo data prove that the particular DMCA is a promising candidate for future in vivo applications.
format	article
author	Maria-Argyro Karageorgou Dimosthenis Stamopoulos
author_facet	Maria-Argyro Karageorgou Dimosthenis Stamopoulos
author_sort	Maria-Argyro Karageorgou
title	Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles
title_short	Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles
title_full	Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles
title_fullStr	Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles
title_full_unstemmed	Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles
title_sort	immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f9189ee69ced4cb9ba8b1377a0369d06
work_keys_str_mv	AT mariaargyrokarageorgou immunocompatibilityofanewdualmodalitycontrastagentbasedonradiolabeledironoxidenanoparticles AT dimosthenisstamopoulos immunocompatibilityofanewdualmodalitycontrastagentbasedonradiolabeledironoxidenanoparticles
_version_	1718386209603977216

Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles

Ejemplares similares